155 S. Limerick Road
411 articles with Teleflex Incorporated
Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 16th Annual Global Healthcare Conference at the Grand Hyatt in New York City, Wednesday, September 12, 2018 at 2:50 p.m. (ET).
Teleflex Announces First Patient Enrollment in Clinical Study Evaluating CleanSweep™ Closed Suction System’s Effects on Ventilator Mechanics Versus a Traditional Closed Suction Catheter
Teleflex Incorporated today announced the first patient enrollment in a U.S. clinical study of CleanSweep™ Closed Suction System at Duke University Hospital in Durham, NC.
Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo Securities 2018 Healthcare Conference at the Westin Copley Place in Boston, MA, Wednesday, September 5, 2018 at 4:10 p.m. (ET).
Second Quarter Revenues of $609.9 million, up 15.4% Versus Prior Year Period; up 12.4% on Constant Currency Basis
Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, August 2, 2018
NeoTract Announces Independent Analysis in UK Confirming Cost Effectiveness of UroLift® System Treatment for Benign Prostatic Hyperplasia (BPH)
Study from Imperial College Health Partners Demonstrates Substantial Economic and Quality of Life Benefits of UroLift System Over Transurethral Resection of the Prostate
NeoTract announced its sponsorship of the fifth annual “Drive for Men’s Health” event.
Teleflex Incorporated will showcase the LMA® Gastro™ Airway and other key products in its Anesthesia portfolio, together with its innovative Vascular Access platform, at the Euroanesthesia Congress.
Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated, is scheduled to speak at the 39th Annual Goldman Sachs Global Healthcare Conference
Teleflex will acquire the Company's commercial coronary products and an option to purchase the drug coated Chocolate Heart™
NeoTract Announces American Urological Association (AUA) Recommendation of UroLift® System as a Standard of Care Option for the Treatment of Enlarged Prostate
UroLift® System recommended as a standard of care treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
Reaffirms 2018 Guidance and Provides 3-Year Financial Goals and Objectives
Teleflex Incorporated announced financial results for the first quarter ended April 1, 2018.
Teleflex Incorporated today announced the agenda for its 2018 Analyst & Investor Day, which will be held on Friday, May 11, 2018.
Teleflex Incorporated announced that financial results for the first quarter 2018 will be released before market open on Thursday, May 3, 2018.
NeoTract Announces Data from Large Real-World Study of UroLift® System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the results from the first analysis of a retrospective registry of more than 800 UroLift® System procedures performed at seven centers in North America, Europe and Australia.
Fourth Quarter 2017 Revenues of $595.1 million, up 15.8% Versus Prior Year Period; up 12.6% on Constant Currency Basis
Teleflex Highlights LMA® Gastro™ Airway Study, Which Shows Efficacy for Use in Upper Gastrointestinal Endoscopy
Peer-Reviewed Published Study Shows Advantages of LMA® Gastro™ Airway
These expanded indications mean that patients who have an obstructive median lobe and those as young as 45 are now eligible to receive treatment with the UroLift System for their BPH symptoms.
An investor conference call will be held at 8:00 a.m. (ET) on Thursday, February 22, 2018.